足月与早产新生儿最佳证据给药推荐(NeoDose项目)的制定
许多药物在新生儿中超说明书使用,导致新生儿重症监护病房(NICU)处方药物和剂量差异很大。NeoDose项目采用三步法:1)药物选择;2)建立基于共识的给药推荐(DRs);3)建立最佳证据DRs。药物选择基于处方频率、荷兰儿科处方集是否已有新生儿DR以及标签状态,并考虑临床需求、药理学多样性和新生儿药理学工作组(WGNP)偏好。第二步从全部十家荷兰NICU获取本地给药方案,在由新生儿科医师、临床药理学家、医院药师和研究人员组成的WGNP内建立共识DRs;第三步用标准化PubMed检索将共识DRs与现有文献比较。最终建立37条最佳证据DRs,其中22条针对早产儿、15条针对足月儿,覆盖19个适应证。
要点
- 从全部十家荷兰NICU收集的14种药物本地给药方案主要在总日剂量、给药频率和/或给药途径上存在差异。
- 几乎所有这些14种药物的给药方案均未区分早产儿与足月儿。
- 工作组建立的共识DRs经文献回顾后56%需要修改,修改主要为增加剂量。
- 最终建立37条最佳证据DRs:22条针对早产儿、15条针对足月儿,覆盖19个适应证。
- 该三步法成功用于制定足月与早产新生儿给药推荐。
适用人群与场景
- 足月新生儿与早产新生儿,用于新生儿重症监护病房(NICU)的药物处方场景。
研究设计与关键结果
- NeoDose项目采用三步法:第一步药物选择(基于处方频率、荷兰儿科处方集是否已有新生儿DR、标签状态,并考虑临床需求、药理学多样性和WGNP偏好);第二步从全部十家荷兰NICU获取本地给药方案并在WGNP内建立共识DRs;第三步用标准化PubMed检索将共识DRs与文献比较。
- 共选择14种药物并收集其本地给药方案,方案主要在总日剂量、给药频率和/或给药途径上存在差异;几乎所有这些方案均未区分早产儿与足月儿。
- 共识DRs经文献回顾后56%需要修改,修改主要为增加剂量。
- 最终建立37条最佳证据DRs,其中22条针对早产儿、15条针对足月儿,覆盖19个适应证。
证据类型、等级与局限
- 证据类型:指南/共识制定项目(NeoDose项目),采用三步法(药物选择、共识DRs建立、最佳证据DRs建立)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
指南或共识出处
- NeoDose项目(Development of Best Evidence Dosing Recommendations for Term and Preterm Neonates)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Many drugs are used off-label in neonates which leads to large variation in prescribed drugs and dosages in neonatal intensive care units (NICUs). The NeoDose project aimed to develop best evidence dosing recommendations (DRs) for term and preterm neonates using a three-step approach: 1) drug selection, 2) establishing consensus-based DRs, and 3) establishing best evidence DRs.
METHODS: The selection of drugs was based on frequency of prescribing, availability of a neonatal DR in the Dutch Pediatric Formulary, and the labeling status. Clinical need, pharmacological diversity, and Working Group Neonatal Pharmacology (WGNP) preferences were also taken into account, using a consensus-based approach. For the second step, we requested local dosing protocols from all ten Dutch NICUs and established consensus-based DRs within the WGNP, consisting of neonatologists, clinical pharmacologists, hospital pharmacists, and researchers. In the third step, the consensus-based DRs were compared with the available literature, using standardized PubMed searches.
RESULTS: Fourteen drugs were selected for which the local dosing protocols were collected. These protocols differed mostly in total daily dose, dosing frequency, and/or route of administration. Strikingly, almost none of the dosing protocols of these 14 drugs distinguished between preterm and term neonates. The working group established consensus-based DRs, which after literature review needed modification in 56%, mainly in terms of a dose increase. Finally, we established 37 best evidence DRs, 22 for preterm and 15 for term neonates, representing 19 indications.
CONCLUSION: This project showed the successful three-step approach for the development of DRs for term and preterm neonates.
参考来源
- de Hoop-Sommen MA, van der Zanden TM, Allegaert K, et al. Development of Best Evidence Dosing Recommendations for Term and Preterm Neonates (NeoDose Project). Neonatology. 2023. PMID: 36646065. doi:10.1159/000528012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。